Pharmacokinetic/Pharmacodynamic Modeling of Total Lymphocytes and Selected Subtypes After Oral Budesonide
- 22 April 2006
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 33 (4) , 441-459
Abstract
In the present pharmacokinetic/pharmacodynamic (PK/PD) evaluation, cortisol, total lymphocytes, and lymphocyte subpopulations were monitored following single oral doses of two oral formulations of 3 mg budesonide (BUD) (Dosage Forms A and B) in order to assess the differential effects that BUD may have on cortisol suppression and the modulation of blood lymphocyte subtypes. On a single occasion, five subjects received one 3 mg capsule of Dosage Form A, four received three capsules of Dosage Form A (single dose of 9 mg), and five received three capsules of Dosage Form B (single dose of 9 mg). Placebo capsules were administered to six subjects in the study. Cortisol concentrations, total lymphocyte counts, and lymphocyte subpopulation counts for the CD3, CD4, CD8, CD19, and CD56/16 were fitted to an in direct PK/PD response model that described the effects of BUD on serum cortisol concentrations as well as the combined effects of BUD and cortisol on total lymphocytes and the CD3, CD4, CD8, CD19, and CD56/16 subtypes. Data were also analyzed using noncompartmental methods. The PK/PD model fitted the data with the exception of data for CD56/16. The IC50 value for unbound BUD acting on total lymphocytes was 0.276 ng/ml while the IC50 values for unbound BUD acting on lymphocyte subtypes ranged from 0.150 ng/ml for CD4 to 0.364 ng/ml for CD8. The IC50 values for the effects of BUD on serum cortisol were lower (0.079 ng/ml). The results of PK/PD modeling and noncompartmental analysis indicate that BUD has a smaller effect on the CD8 subtype and larger effects on the CD4 and CD19 subtypes, relative to the effect on total lymphocytes, and that cortisol suppression, although not a direct immunological biomarker, may be a more sensitive marker for the systemic effect of corticosteroids.Keywords
This publication has 41 references indexed in Scilit:
- New Developments in CorticosteroidsProceedings of the American Thoracic Society, 2004
- An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapyAAPS PharmSci, 2000
- Diltiazem retards the metabolism of oral prednisone with effects on T‐cell markersPediatric Transplantation, 1999
- Impact of pharmacodynamic variability on drug delivery1Advanced Drug Delivery Reviews, 1998
- Osteocalcin, growth, and inhaled corticosteroids: a prospective study.Archives of Disease in Childhood, 1996
- BudesonideDrugs, 1995
- Differential mood response to natural and synthetic corticosteroids after bilateral adrenalectomy: A case reportJournal of Psychiatric Research, 1994
- Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of CorticosteroidsThe Journal of Clinical Pharmacology, 1993
- Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in manJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Pharmacokinetics and Oral Bioavailability of HydrocortisoneThe Journal of Clinical Pharmacology, 1991